Huang 2013.

Methods	Multicentre RCT 2 arms Quality score: D
Participants	n = 240 Median age: 55 years Metastatic disease: 93%
Interventions	Paclitaxel+S‐1: Paclitaxel 60 mg/m2 d 1,8,15, S‐1 depending on body surface area (BSA < 1.25 m2: 80 mg/d; BSA 1.25 to <1.5 m2: 100 mg/d; BSA > 1.5 m2, 120 mg/d twice daily) twice daily d 1‐14, repeated at d 29 versus Paclitaxel+5‐FU: Paclitaxel 60 mg/m2 d 1,8,15, 5‐FU 500mg/m2 d 1‐5, leucovorin 20 mg/m2 d 1‐5 repeated at d 29
Outcomes	Response rates Progression‐free survival Time to treatment failure Toxicity
Notes	6% of patients had no adenocarconoma
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not mentioned
Allocation concealment (selection bias)	Low risk	Central randomisation
Incomplete outcome data (attrition bias) efficacy	Low risk	229/240 included in full analysis set: One patient was not eligible for the current analysis due to a lack of measurable lesions, 11 patients withdrew informed consent
Incomplete outcome data (attrition bias) safety	Low risk	229/240 included in full analysis set: One patient was not eligible for the current analysis due to a lack of measurable lesions, 11 patients withdrew informed consent
Selective reporting (reporting bias)	Low risk	All expected outcomes except OS analysed
Other bias	Unclear risk	OS not analysed
Blinded review of CT/MRI‐scans?	Unclear risk	Not stated